Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy.

Pieribone VA, Tsai J, Soufflet C, Rey E, Shaw K, Giller E, Dulac O.

Epilepsia. 2007 Oct;48(10):1870-4. Epub 2007 Jul 18.

2.

Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial.

Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, Pellock JM, Morton LD, Monaghan EP.

Epilepsy Res. 2000 Dec;42(2-3):133-9.

PMID:
11074186
3.

Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group.

Laxer K, Blum D, Abou-Khalil BW, Morrell MJ, Lee DA, Data JL, Monaghan EP.

Epilepsia. 2000 Sep;41(9):1187-94.

4.

Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.

Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, Vajda FJ.

Epilepsy Res. 2005 Jan;63(1):1-9. Epub 2005 Jan 6.

PMID:
15716083
5.

Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.

Shinnar S, Pellock JM, Conry JA.

Eur J Paediatr Neurol. 2009 Jan;13(1):3-9. doi: 10.1016/j.ejpn.2008.01.004. Epub 2008 Mar 14.

PMID:
18343174
6.

Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity.

Monaghan EP, Navalta LA, Shum L, Ashbrook DW, Lee DA.

Epilepsia. 1997 Sep;38(9):1026-31.

7.

Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.

Callenbach PM, Arts WF, ten Houten R, Augustijn P, Gunning WB, Peeters EA, Weber AM, Stroink H, Geerts Y, Geerts AT, Brouwer OF.

Eur J Paediatr Neurol. 2008 Jul;12(4):321-7. Epub 2007 Oct 18.

PMID:
17950011
8.

The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.

Steinhoff BJ, Somerville ER, Van Paesschen W, Ryvlin P, Schelstraete I.

Epilepsy Res. 2007 Aug;76(1):6-14. Epub 2007 Aug 6.

PMID:
17681453
9.

[Safety of levetiracetam as adjunctive therapy in epilepsy: the SKATE trial in Spain].

Salas-Puig J, Serratosa JM, Viteri C, Gil-Nágel-Rein A; Grupo Español del Estudio SKATE.

Rev Neurol. 2004 Jun 16-30;38(12):1117-22. Spanish.

10.

Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures.

Sperling MR, Klein P, Tsai J.

Epilepsia. 2017 Apr;58(4):558-564. doi: 10.1111/epi.13705. Epub 2017 Feb 23.

PMID:
28230252
11.

Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study.

Coppola G, Grosso S, Verrotti A, Parisi P, Luchetti A, Franzoni E, Mangano S, Pelliccia A, Operto FF, Iannetti P, Curatolo P, Balestri P, Pascotto A.

Epilepsy Res. 2009 Feb;83(2-3):112-6. doi: 10.1016/j.eplepsyres.2008.10.012. Epub 2008 Dec 10.

PMID:
19081227
12.

Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.

Kluger G, Kurlemann G, Haberlandt E, Ernst JP, Runge U, Schneider F, Makowski C, Boor R, Bast T.

Epilepsy Behav. 2009 Mar;14(3):491-5. doi: 10.1016/j.yebeh.2008.12.013. Epub 2009 Jan 20.

PMID:
19162229
13.

Levetiracetam: a long-term follow-up study of efficacy and safety.

Bauer J, Ben-Menachem E, Krämer G, Fryze W, Da Silva S, Kasteleijn-Nolst Trenité DG.

Acta Neurol Scand. 2006 Sep;114(3):169-76.

PMID:
16911344
14.

Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone.

Beekman M, Ungard JT, Gasior M, Carter RB, Dijkstra D, Goldberg SR, Witkin JM.

J Pharmacol Exp Ther. 1998 Mar;284(3):868-77.

15.

Long-term use of zonisamide in refractory childhood-onset epilepsy.

Kluger G, Zsoter A, Holthausen H.

Eur J Paediatr Neurol. 2008 Jan;12(1):19-23. Epub 2007 Jun 18.

PMID:
17574461
16.

Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy.

Remy C, Beaumont D.

Br J Clin Pharmacol. 1989;27 Suppl 1:125S-129S.

17.

Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.

Ferrendelli JA, French J, Leppik I, Morrell MJ, Herbeuval A, Han J, Magnus L.

Epilepsy Behav. 2003 Dec;4(6):702-9.

PMID:
14698704
18.

[Experience with levetiracetam in childhood epilepsy].

Neuwirth M, Saracz J, Hegyi M, Paraicz E, Kollár K, Móser J, Rosdy B, Herczegfalvi A, Fogarasi A.

Ideggyogy Sz. 2006 May 20;59(5-6):179-82. Hungarian.

PMID:
16786712
19.
20.

Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.

Peltola J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavaskiy L, Lu ZS, Sykes DM; Levetiracetam XR N01235 Study Group.

Epilepsia. 2009 Mar;50(3):406-14. doi: 10.1111/j.1528-1167.2008.01817.x.

Supplemental Content

Support Center